key: cord-0798156-igtalkyh
authors: Imani, Mohammad Moslem; Sadeghi, Masoud; Farokhzadeh, Farid; Khazaie, Habibolah; Brand, Serge; Dürsteler, Kenneth M.; Brühl, Annette; Sadeghi-Bahmani, Dena
title: Evaluation of Blood Levels of C-Reactive Protein Marker in Obstructive Sleep Apnea: A Systematic Review, Meta‐Analysis and Meta-Regression
date: 2021-04-19
journal: Life (Basel)
DOI: 10.3390/life11040362
sha: 41bdb87602da9e2ad1f6e0f2d211296721696c70
doc_id: 798156
cord_uid: igtalkyh

(1) Introduction: High sensitivity C-reactive protein (hs-CRP) and CRP are inflammatory biomarkers associated with several inflammatory diseases. In both pediatric and adult individuals with Obstructive Sleep Apnea (OSA) higher hs-CRP and CRP were observed, compared to controls. With the present systematic review, meta-analysis and meta-regression we expand upon previous meta-analyses in four ways: (1) We included 109 studies (96 in adults and 13 in children); (2) we reported subgroup and meta-regression analyses in adults with OSA compared to controls on the serum and plasma levels of hs-CRP; (3) we reported subgroup and meta-regression analyses in adults with OSA compared to controls on the serum and plasma levels of CRP; (4) we reported serum and plasma levels of both hs-CRP and CRP in children with OSA, always compared to controls. (2) Materials and Methods: The PubMed/Medline, Scopus, Cochrane Library, and Web of Science databases were searched to retrieve articles published until 31 May 2020, with no restrictions. The data included basic information involving the first author, publication year, country of study, ethnicity of participants in each study, age, BMI, and AHI of both groups, and mean and standard deviation (SD) of plasma and serum levels of CRP and hs-CRP. (3) Results: A total of 1046 records were retrieved from the databases, and 109 studies were selected for the analysis (96 studies reporting the blood levels of hs-CRP/CRP in adults and 13 studies in children). For adults, 11 studies reported plasma hs-CRP, 44 serum hs-CRP, 9 plasma CRP, and 32 serum CRP levels. For children, 6 studies reported plasma hs-CRP, 4 serum hs-CRP, 1 plasma CRP, and 2 serum CRP levels. Compared to controls, the pooled MD of plasma hs-CRP levels in adults with OSA was 0.11 mg/dL (p < 0.00001). Compared to controls, the pooled MD of serum hs-CRP levels in adults with OSA was 0.09 mg/dL (p < 0.00001). Compared to controls, the pooled MD of plasma CRP levels in adults with OSA was 0.06 mg/dL (p = 0.72). Compared to controls, the pooled MD of serum CRP levels in adults with OSA was 0.36 mg/dL (p < 0.00001). Compared to controls, the pooled MD of plasma hs-CRP, serum hs-CRP, plasma hs-CRP, and serum hs-CRP in children with OSA was 1.17 mg/dL (p = 0.005), 0.18 mg/dL (p = 0.05), 0.08 mg/dL (p = 0.10), and 0.04 mg/dL (p = 0.33), respectively. The meta-regression showed that with a greater apnea-hypapnea index (AHI), serum hs-CRP levels were significantly higher. (4) Conclusions: The results of the present systematic review, meta-analysis and meta-regression showed that compared to healthy controls plasma and serum levels of hs-CRP and serum CRP level were higher in adults with OSA; for children, and compared to controls, just plasma hs-CRP levels in children with OSA were higher.

We included 109 studies (96 in adults and 13 in children) 2.

We reported subgroup and meta-regression analyses in adults with OSA compared to controls on the serum and plasma levels of hs-CRP

The characteristics of the studies entered in the analysis are shown in Table 1 . Of the 109 studies, 96 studies reported blood levels of hs-CRP/CRP in adults, and 13 studies reported blood levels of hs-CRP/CRP in children. The studies were published from 2002 to 2020. Of the 96 studies on blood levels of hs-CRP/CRP in adults, 11 studies reported plasma hs-CRP, 44 studies reported serum hs-CRP, 9 studies reported plasma CRP, and 32 studies reported serum CRP levels. Six out of 13 studies in children reported plasma hs-CRP, 4 studies reported serum hs-CRP, one study reported plasma CRP, and 2 studies reported serum CRP levels. Abbreviations: NR, Not reported; OSA, Obstructive sleep apnea; AHI, Apnea-hypopnea index; BMI, Body mass index (based on kg/m 2 in adults and Z-score in children); CRP, C-reactive protein; hs-CRP, High-sensitivity CRP.

Eleven studies of plasma hs-CRP levels in adults involved 1365 individuals with OSA and 1629 controls ( Table 2 ). The pooled MD of plasma hs-CRP levels in individuals with OSA in comparison to controls was 0.11 mg/dL [95% CI: 0.07, 0.16; p < 0.00001; I 2 = 89% (P heterogeneity or p h < 0.00001)]. Thus, plasma hs-CRP levels were significantly higher in individuals with OSA than in controls. 

Forty-four studies of serum hs-CRP levels in adults involved 3857 individuals with OSA and 1240 controls ( Table 3 ). The pooled MD of serum hs-CRP levels in individuals with OSA in comparison to controls was 0.09 mg/dL [95% CI: 0.07, 0.11; p < 0.00001; I 2 = 96% (p h < 0.00001)]. Thus, serum hs-CRP levels were significantly higher in individuals with OSA than in controls. 

Nine studies of plasma CRP levels in adults involved 592 individuals with OSA and 346 controls ( Table 4 ). The pooled MD of plasma CRP levels in individuals with OSA in comparison to controls was 0.06 mg/dL [95% CI: −0.24, 0.36; p = 0.72; I 2 = 99% (p h < 0.00001)]. Thus, plasma CRP levels had no significant difference in individuals with OSA compared to controls. 

Thirty-two studies of serum CRP levels in adults involved 2562 individuals with OSA and 1315 controls ( Table 5 ). The pooled MD of serum CRP levels in individuals with OSA in comparison to controls was 0.36 mg/dL [95% CI: 0.28, 0.45; p < 0.00001; I 2 = 96% (p h < 0.00001)]. Thus, serum CRP levels were significantly higher in individuals with OSA than in controls.

Six studies of plasma hs-CRP levels involved 600 children with OSA and 704 controls, four studies of serum hs-CRP levels involved 177 individuals with OSA and 95 controls, one study of plasma CRP levels involved 84 individuals with OSA and 22 controls, and two studies of serum CRP levels involved 93 individuals with OSA and 69 controls, in children ( Table 6 ). The pooled MD of plasma hs-CRP, serum hs-CRP, plasma hs-CRP, and serum hs-CRP in individuals with OSA in comparison to controls was 1.17 mg/dL [95% CI: 0.35, 1.98; p = 0.005; I 2 = 94% (p h < 0.00001)], 0.18 mg/dL [95% CI: −0.00, 0.35; p = 0.05; I 2 = 98% (p h < 0.00001)], 0.08 mg/dL [95% CI: − 0.02, 0.18; p = 0.10], and 0.04 mg/dL [95% CI: −0.04, 0.13; p = 0.33; I 2 = 0% (p h = 0.36)], respectively. Thus, just plasma hs-CRP levels were significantly higher in individuals with OSA than in controls. Subgroup analyses of plasma and serum hs-CRP levels in adults are reported in Table 7 . The pooled analysis showed that for those with OSA, plasma hs-CRP levels in Caucasian (MD = 0.10 mg/dL, p = 0.004) and Asian (MD = 0.12 mg/dL, p = 0.003) ethnicities were significantly higher than the plasma hs-CRP levels of the respective controls, not for and mixed ethnicity (MD = 0.24 mg/dL, p = 0.47). In addition, the pooled analysis showed that for those with OSA, serum hs-CRP levels in Caucasian (MD = 0.18 mg/dL, p < 0.00001) and Asian (MD = 0.08 mg/dL, p < 0.00001) ethnicities were significantly higher than the serum hs-CRP levels of the respective controls, not for mixed ethnicity (MD = 0.05 mg/dL, p = 0.28). Therefore, ethnicity could be an effective factor on the serum and plasma levels of hs-CRP as the significant difference was found for Asian and Caucasian ethnicities, not for mixed ethnicity. Table 6 . Forest plot of random-or fixed-effects analysis of plasma and serum levels of high-sensitivity C-reactive protein (hs-CRP) and CRP in children. Abbreviations: OSA, Obstructive sleep apnea; CI, Confidence interval; C-reactive protein; hs-CRP, High-sensitivity CRP; SD, Standard deviation. All analyses were performed based on random-effects model, except serum hs-CRP was based on fixed-effects model.

With regards to mean BMI of participants with OSA, the pooled MD of plasma hs-CRP levels of individuals with OSA was significantly higher than in controls, irrespective of their BMI: mean BMI ≤ 30 kg/m 2 (MD = 0.11 mg/dL, p = 0.003), but there was no for mean BMI > 30 kg/m 2 (MD = 0.10 mg/dL, p = 0.15). The pooled MD of serum hs-CRP levels of individuals with OSA was significantly higher than in controls, irrespective of their BMI: mean BMI > 30 kg/m 2 (MD = 0.18 mg/dL, p < 0.0001); or mean BMI ≤ 30 kg/m 2 (MD = 0.08 mg/dL, p < 0.00001). With regards to mean BMI of controls, the pooled MD of plasma hs-CRP levels was significantly higher in individuals with OSA compared to controls, irrespective of whether the BMI of controls was ≤30 kg/m 2 (MD = 0.11 mg/dL, p < 0.001), but there was no significant difference for mean BMI > 30 kg/m 2 (MD = 0.15 mg/dL, p = 0.30). The pooled MD of serum hs-CRP levels of individuals with OSA was significantly higher than in controls, irrespective of whether the BMI of controls was >30: mean BMI > 30 kg/m 2 (MD = 0.11 mg/dL, p = 0.004); or mean BMI ≤ 30 kg/m 2 (MD = 0.09 mg/dL, p < 0.00001). Therefore, BMI could be an effective factor on the plasma level of hs-CRP as the significant difference was found for participants with BMI ≤ 30 kg/m 2 , not for BMI > 30 kg/m 2 . However, BMI couldn't be an effective factor on the serum level of hs-CRP.

With regard to the number of participants in each study, the pooled MD of plasma hs-CRP levels in those studies with more than 100 cases across OSA and control groups was 0.14 mg/dL (p = 0.04); the pooled MD of the studies with ≤100 cases across the two groups was 0.11 mg/dL (p < 0.0002). In contrast, the MD of serum hs-CRP levels in studies with more than 100 cases was 0.10 mg/dL (p < 0.00001), and in studies with less than 100 cases across two groups was 0.08 mg/dL (p < 0.00001). Therefore, number of participants couldn't be an effective factor on the plasma and serum levels of hs-CRP. Table 7 . Subgroup analysis on serum and plasma levels of high-sensitivity C-reactive protein (hs-CRP) in adult participants. 

With regard to the mean AHI of participants with OSA, the pooled MD of plasma hs-CRP levels in the studies including a mean AHI > 30 events/h was 0.14 mg/dL (p = 0.02); the pooled MD of the studies with a mean AHI ≤ 30 events/h was 0.10 mg/dL (p = 0.01). In contrast, the MD of serum hs-CRP levels in the studies including a mean AHI > 30 events/h was 0.11 mg/dL (p < 0.00001) and in the studies including a mean AHI ≤ 30 events/h was 0.07 mg/dL (p < 0.00001). Therefore, AHI couldn't be an effective factor on the plasma and serum levels of hs-CRP.

Subgroup analyses of plasma and serum CRP levels in adults are reported in Table 8 . The pooled analysis showed that for those with OSA, there was no significant difference for plasma CRP levels in Caucasian (MD = 0.22 mg/dL, p = 0.39) and Asian (MD = 0.21 mg/dL, p = 0.18) ethnicities, compared to the respective controls. In addition, the pooled analysis showed that for those with OSA, serum CRP levels in Caucasian (MD = 0.38 mg/dL, p < 0.00001) and Asian (MD = 0.38 mg/dL, p < 0.00001) ethnicities were significantly higher than serum CRP levels of the respective controls, not for mixed ethnicity (MD = 0.06 mg/dL, p = 0.37). Therefore, ethnicity couldn't be an effective factor on the plasma and serum levels of CRP. 

With regards to mean BMI of participants with OSA, the pooled MD of plasma CRP levels had no significant difference in individuals with OSA compared to controls, irrespective of their BMI: mean BMI ≤ 30 kg/m 2 (MD = 0.95 mg/dL, p = 0.001). In contrast, for mean BMI > 30 kg/m 2 (MD = −0.088 mg/dL, p = 0.04) pooled MD of plasma CRP levels was significantly lower than in controls. The pooled MD of serum CRP levels of individuals with OSA was significantly higher than in controls, irrespective of their BMI: mean BMI > 30 kg/m 2 (MD = 0.31 mg/dL, p < 0.00001); or mean BMI ≤ 30 kg/m 2 (MD = 0.41 mg/dL, p < 0.00001). With regards to mean BMI of controls, there was no significant difference for the pooled MD of plasma CRP levels in individuals with OSA, compared to controls, whether the BMI of controls was ≤30 kg/m 2 (MD = 0.06 mg/dL, p = 0.72); further, there was no study with individuals with a mean BMI > 30 kg/m 2 . The pooled MD of serum CRP levels of individuals with OSA was significantly higher than in controls in those studies including a mean BMI > 30 kg/m 2 (MD = 0.61 mg/dL, p = 0.002); or mean BMI ≤ 30 kg/m 2 (MD = 0.35 mg/dL, p < 0.00001) in controls. Therefore, BMI couldn't be an effective factor on serum levels of CRP.

With regard to the number of participants in each study, the pooled MD of plasma CRP levels in the studies including ≤100 cases across OSA and control groups was 0.69 mg/dL (p = 0.0003), and there was no significant difference for the studies including more than 100 cases across the two groups (MD = −1.43 mg/dL (p = 0.14). In contrast, the MD of serum CRP levels in the studies with >100 cases was 0.21 mg/dL (p = 0.0003) and in the studies including ≤100 cases across two groups was 0.53 mg/dL (p < 0.00001). Therefore, the number of participants could be an affective factor on plasma levels of CRP as the significant difference was found for the studies with ≤100 cases, not for >100 cases. However, the number of participants couldn't be an affective factor on serum levels of CRP.

With regard to the mean AHI of participants with OSA, the pooled MD of plasma CRP levels in the studies including a mean AHI ≤ 30 events/h was 0.18 mg/dL (p = 0.02), and there was no significant difference for the studies with a mean AHI ≤ 30 events/h (MD = 1.64 mg/dL (p = 0.16). In contrast, the MD of serum CRP levels in the studies including a mean AHI > 30 events/h was 0.54 mg/dL (p < 0.00001) and in the studies including a mean AHI ≤ 30 events/h was 0.27 mg/dL (p < 0.00001). Therefore, AHI could be an affective factor on plasma levels of CRP as the significant difference was found for the studies with AHI ≤ 30 events/h, not for AHI > 30 events/h. However, AHI couldn't be an affective factor on serum levels of CRP.

The results of meta-regression of plasma and serum hs-CRP levels are shown in Table 9 . The year of publication, mean age, mean BMI, and number of participants had no independent significant effects on serum or plasma hs-CRP levels, whereas with greater AHI, serum hs-CRP levels were significantly higher. Table 9 . Meta-regression analysis based on some variables for serum and plasma levels of high-sensitivity C-reactive protein (hs-CRP) in obstructive sleep apnea patients compared with controls in adult participants. 

The results of meta-regression of plasma and serum CRP levels are shown in Table 10 . The year of publication, mean age, mean BMI, mean AHI, and number of participants had no independent significant effects on serum or plasma CRP levels.

The quality scores of the studies included in the analysis are shown in Table 11 .

The "cumulative analysis" and the "one study removed" as two sensitivity analyses revealed the stability of the results in adults and in children.

The funnel plots of the analysis of plasma and serum levels of CRP and hs-CRP are shown in Figure 2 , and Table 12 shows the results of the trim-and-fill method on bias. Table 10 . Meta-regression analysis based on some variables for serum and plasma levels of C-reactive protein (CRP) in obstructive sleep apnea patients compared with controls in adult participants. [35] *** ** *** 8 Barceló, 2004 [36] *** ** *** 8 Guilleminault, 2004 [37] **** * *** 8 Minoguchi, 2005 [38] *** ** *** 8 Can, 2006 [39] *** ** *** 8 Minoguchi, 2006 [40] *** ** *** 8 Shiina, 2006 [41] **** ** *** 9 Ryan, 2007 [42] *** ** *** 8 Chung, 2007 [43] *** ** *** 8 Iesato, 2007 [44] **** ** *** 9 Minoguchi, 2007 [45] **** ** *** 9 Jin, 2007 [46] *** ** *** 8 Kapsimalis, 2008 [47] **** ** *** 9 Saletu, 2008 [48] *** ** *** 8 Sharma, 2008 [49] **** ** *** 9 Takahashi, 2008 [50] *** ** *** 8 Bhushan, 2009 [51] *** ** *** 8 Carneiro, 2009 [52] *** ** *** 8 Cofta, 2009 [53] *** ** *** 8 Makino, 2009 [54] *** ** *** 8 Sahlman, 2010 [55] *** ** *** 8 Aihara, 2011 [56] *** * *** 8 Barceló, 2011 [57] *** ** *** 8 Basoglu, 2011 [58] *** ** *** 8 Fredheim, 2011 [59] *** * *** 8 Guasti, 2011 [60] **** ** *** 9 [62] *** * *** 7 Balci, 2012 [63] *** ** *** 8 Chien, 2012 [64] *** ** *** 8 Feng, 2012 [65] *** ** *** 8 Fornadi, 2012 [66] *** ** *** 8 Guven, 2012 [67] *** ** *** 8 Panoutsopoulos, 2012 [68] *** ** *** 8 Chen, 2013 [69] *** * *** 7 Kosacka, 2013 [70] *** ** *** 8 Wang, 2013 [71] *** ** *** 8 Zhang, 2013 [72] *** ** *** 8 Akilli, 2014 [73] *** ** *** 8 Ciccone, 2014 [74] *** ** *** 8 Li, 2014 [75] *** ** *** 8 Niżankowska-Jędrzejczyk, 2014 [76] *** ** *** 8 Shi, 2014 [77] *** ** *** 8 Sökücü, 2014 [78] *** * *** 7 Yadav, 2014 [79] **** ** *** 9 Yüksel, 2014 [80] *** * *** 7 Abakay, 2015 [81] *** ** *** 8 Andaku, 2015 [82] *** ** *** 8 da Silva Araújo, 2015 [83] *** ** *** 8 Asker, 2015 [84] *** -*** 6 Bakırcı, 2015 [85] *** ** *** 8 Kanbay, 2015 [81] *** ** *** 8 Korkmaz, 2015 [86] *** ** *** 8 Xu, 2015 [87] *** ** *** 8 Altintas, 2016 [88] *** ** *** 8 Archontogeorgis, 2016 [89] *** ** *** 8 Borratynska, 2016 [90] **** ** *** 9 Can, 2016 [91] *** ** *** 8 Cao, 2016 [92] *** ** *** 8 Kim, 2016 [93] *** ** *** 8 Qi, 2016 [94] *** ** *** 8 Tanrıverdi, 2016 [95] *** ** *** 8 Tie, 2016 [96] *** ** *** 8 Vicente, 2016 [97] *** ** *** 8 Uygur, 2016 [98] *** ** *** 8 Zhang, 2016 [99] *** ** *** 8 Bouloukaki, 2017 [100] *** * *** 7 Gamsiz-Isik, 2017 [101] *** ** *** 8 Karamanli, 2017 [102] *** ** *** 8 Kosacka, 2017 [103] *** ** *** 8 Suliman, 2017 [104] *** ** *** 8 Xu, 2017 [105] **** ** *** 9 Bozic, 2018 [106] *** ** *** 8 Bozkus, 2018 [107] *** * *** 7 Cengiz, 2018 [108] *** ** *** 8 Horvath, 2018 [109] *** * *** 7 Kunos, 2018 [110] *** * *** 7 Ozkok, 2018 [111] *** ** *** 8 Ye, 2018 [112] *** ** *** 8 Zhang, 2018 [113] *** ** *** 8 Bhatt, 2019 [114] *** -*** 6 Jung, 2019 [115] *** ** *** 8 Li, 2019 [116] *** ** *** 8 Płóciniczak, 2019 [117] *** * *** 7 Voulgaris, 2019 [118] *** ** *** 8 Wang, 2019 [119] *** ** *** 8 Wen, 2019 [120] *** ** *** 8 Bocskei, 2020 [121] *** * *** 7 Chen, 2020 [122] *** ** *** 8 

Chien, 2020 [123] *** ** *** 8 Düger, 2020 [124] *** ** *** 8 Pákó, 2020 [125] *** ** *** 8 Winiarska, 2020 [126] *** ** *** 8 Xie, 2020 [127] *** * *** 8 Zhang, 2020 [128] **** ** *** 9

Kaditis, 2010 [129] *** * *** 7 Kheirandish-Gozal, 2010 [130] *** * *** 7 Kim, 2010 [4] **** * *** 8 Canapari, 2011 [131] *** * *** 7 Khalyfa, 2012 [132] **** ** *** 9 Kim, 2013 [133] **** ** *** 9 Iannuzzi, 2013 [134] **** ** *** 9 Israel, 2013 [135] *** ** *** 8 Gozal, 2014 [136] **** ** *** 9 Kheirandish-Gozal, 2014 [137] **** ** *** 9 Ye, 2015 [138] *** ** *** 8 Huang, 2016 [139] *** * *** 7 Smith, 2017 [3] **** ** *** 9

Each asterisk denotes 1 point.

For plasma and serum hs-CRP levels, Egger's test (p = 0.86142 and p = 0.06867, respectively) and Begg's test (p = 0.93795 and p = 0.10132, respectively) indicated no bias either between or across the studies.

For plasma hs-CRP levels without imputed studies, under the fixed-effects model, the point estimate and 95% CI for the combined studies is 0.114 (0.097, 0.130); using the trim-fill method, the imputed point estimate is similar. In addition, under the random-effects model, the point estimate and 95% CI for the combined studies is 0.115 (0.064, 0.0166); using the trim-fill method, the imputed point estimate is similar. For serum hs-CRP levels and 14 imputed studies, under the fixed-effects model, the point estimate and 95% CI for the combined studies is 0.049 (0.047, 0.052), and using trim-fill method, the imputed point estimate is 0.049 (0.046, 0.051). In addition, under the random-effects model, the point estimate and 95% CI for the combined studies is 0.089 (0.069, 0.109); using the trim-fill method, the imputed point estimate is 0.059 (0.038, 0.080). These findings showed that the overall effect sizes for serum and plasma hs-CRP levels reported in the forest plot appeared to be valid, with a trivial publication bias effect based on fixed-effects or random-effects models, because the observed estimates were similar to the adjusted estimates.

For plasma and serum CRP levels, Egger's test (p = 0.98284 and p = 0.00341, respectively) revealed a bias for serum level, but not for plasma level, and Begg's test (p = 0.53161 and p = 0.16860, respectively) indicated no bias either between or across the studies for both samples.

For plasma CRP levels and one imputed study, under the fixed-effects model, the point estimate and 95% CI for the combined studies was 0.131 (0.096, 0.165); using the trim-fill method, the imputed point estimate was 0.125 (0.91, 0.160). In addition, under the random-effects model, the point estimate and 95% CI for the combined studies was 0.107 (−0.256, 0.471); using the trim-fill method, the imputed point estimate was −0.317 (−0.721, 0.087). For serum CRP levels and 13 imputed studies, under the fixed-effects model, the point estimate and 95% CI for the combined studies was 0.094 (0.079, 0.108), and using trim-fill method, the imputed point estimate was 0.55 (0.41, 0.69). In addition, under the random-effects model, the point estimate and 95% CI for the combined studies was 0.304 (0.216, 0.391); using the trim-fill method, the imputed point estimate was 0.083 (−0.011, 0.177). These findings showed that the overall effect sizes for CRP levels reported in the forest plot appeared to be valid, with a trivial publication bias effect based on fixedeffects model for plasma level, because the observed estimates were similar to the adjusted estimates. In contrast, the overall effect sizes on CRP levels reported in the forest plot appeared to be invalid, with a significant publication bias effect based on random-effects model for both samples (serum and plasma levels) and fixed-effects model for serum level, because the observed estimates were substantially different to the adjusted estimates. 

The main findings of the present systematic review, meta-analysis and meta-regression on the plasma and serum levels of hs-CRP and CRP in adults and children were as follows:

1.

serum and plasma hs-CRP levels and serum CRP levels in adults were significantly higher in individuals with OSA than in controls.

there was no significant difference in adults with OSA compared to controls for plasma levels of CRP. 3.

in children, just plasma hs-CRP levels were significantly higher in pediatric individuals with OSA, compared to controls. 4.

based on subgroup analysis for the plasma and serum levels of hs-CRP, ethnicity and mean BMI in individuals with OSA could impact on the results of plasma hs-CRP levels, and ethnicity on serum levels of hs-CRP. 5.

based on subgroup analysis for the plasma and serum levels of CRP, number of participants and mean AHI in individuals with OSA could impact on plasma CRP levels, and ethnicity on serum levels of CRP. 6.

based on meta-regression on the plasma and serum levels of hs-CRP and CRP, just mean AHI of individuals with OSA could be an interfering factor on the results of serum levels of hs-CRP.

It follows that with the present meta-analysis, systematic review and meta-regression, we were able to show that inflammatory markers, here hs-CRP and CRP, are increased in individuals with OSA, though, the pattern of results is not straightforward and uniform; rather, hs-CRP and CRP levels might be higher compared to, or equal to hs-CRP and CRP levels of healthy controls, depending of the blood samples (serum vs. plasma), age (children vs. adults), ethnicity, BMI, sample size and AHI-cut-off values. Given this, it seems conceivable that previous and present results on the associations between hs-CRP and CRP in individuals with OSA appear inconsistent.

Indeed, there were conflicting results for the associations between OSA and hs-CRP [33, 52, 59, 60, 80, 104] or CRP [36, 57, 61, 65] levels. One meta-analysis [19] included 25 studies reporting the blood levels of CRP in individuals with and without OSA. Its results showed that the pooled standardized mean difference in adults with OSA compared to controls was 1.77 (p < 0.0001). Three meta-analyses [20] [21] [22] showed serum levels of hsCRP and/or CRP elevated in individuals with OSA compared to controls. The results were in line with our meta-analysis for serum levels, but not plasma levels. Therefore, the type of sample for measuring CRP appears to be important in adults with OSA; however, there was no difference between both samples (plasma or serum) for measuring hs-CRP in our meta-analysis. The meta-regression in the meta-analysis [19] showed significant effects of age, BMI, and AHI on CRP levels similar to the results of the study of Kanbay et al. [140] . In contrast, the meta-regression didn't show the effect of these factors on serum or plasma levels of CRP; rather, just AHI had a significant effect on serum levels of hs-CRP. Further, in line with two studies [43, 46] , age was not associated with CRP levels. To explain these con-flicting results, it is conceivable that a higher number of studies and the separate analysis of both serum and plasma yielded these differences between the present and former analyses.

For OSA, the following risk factors were reported: Older age, male gender, obesity, heavy drinking, smoking, and anatomical abnormalities, though, obesity appeared to be the strongest risk factor [141] . CRP is a sensitive marker for systemic inflammation, with increased plasma levels in this acute phase reactor indicating increased inflammatory activity in humans. Further, CRP can also be a substitute biomarker of low-grade inflammation related to obesity [58] : Studies [36, 42, 46] reported that CRP levels were significantly higher in obese individuals with OSA, compared to non-obese individuals with OSA. In contrast, Jung et al. [115] showed that there was no association between BMI and hs-CRP levels and in our meta-analysis, the mean BMI couldn't be an effective factor on the plasma and serum levels of CRP and hs-CRP.

There were relationships between OSA severity and CRP [33, 35, 64, 92] and hs-CRP [100, 106, 123] levels. One study [142] showed that hs-CRP levels were related to OSA independently of visceral obesity. Jin et al. [46] reported that serum CRP levels positively correlated with AHI. In our meta-analysis, mean AHI couldn't be an affective factor on serum levels of CRP. In our subgroup analyses, we found that hs-CRP and CRP levels in the studies with a mean AHI ≤ 30 events/h were higher than in those studies with a mean AHI > 30 events/h. Further, AHI was just a confounding factor for serum hs-CRP levels and our AHI couldn't be an affective factor on the plasma and serum levels of CRP and hs-CRP.

In children, there was just the association between the plasma hs-CRP level and OSA with a higher level in the participants with OSA compared to the controls. A lack of association for the serum hs-CRP, plasma CRP, and serum CRP could be due to few include studies.

To explain the associations between hs-CRP, plasma CRP and serum CRP, the following assumptions were made: First, C-reactive protein (CRP) is regarded as a significant serum marker of inflammation; as such, CRP is synthesized in the liver, mainly regulated via the expression of IL-6 [13] . IL-6 concentrations are increased in individuals with OSA(S), compared to healthy controls [12] . As such, it appears plausible that higher IL-6 concentrations are associated with higher h-CRP, plasma and serum CRP concentrations. Second, higher CRP concentrations were observed among individuals at increased risk of cardiovascular diseases, such as atherosclerosis, stroke, and myocardial infarction [100, 143] . As such, it appeared conceivable that increased serum CRP levels could predict complications such as atherosclerosis [100, 143] . In this view, long-term sustained hypoxia could yield activated inflammatory responses with elevated levels of proinflammatory cytokines [144] .

The novelty of the results should be balanced against the following limitations: First, in all studies the results were not adjusted based on possible confounding factors such as obesity, smoking, and alcohol consumption, and even in some studies based on gender. Second, there was a high heterogeneity and also a bias between and across studies, all of which could impact on the reliability of the results. Third, studies with a small sample size (less than 100) might have had insufficient power to detect associations between OSA, CRP and hs-CRP levels. Fourth, studies reported various cut-off AHI values, which made it difficult to compare the study results. Fifth, in some studies, CRP and hs-CRP levels were considered as a secondary outcome.

By contrast, the meta-analysis had several strengths: First, the meta-regression showed that higher AHI could be a cofounder factor on serum hs-CRP levels. Second, there were sufficient studies to allow the subgroup analysis. Third, sensitivity analysis illustrated the consistency of results. Fourth, we included the studies written in any language. Fifth, unlike previous meta-analyses, we included also data of children with OSA.

Last, while we focused on significant p-values, we did less rely on effect size calculation. However, a closer inspection showed that when focusing on effect sizes, the overall pattern of results did not change.

The findings of this systematic review, meta-analysis and meta-regression demonstrated that higher plasma and serum levels of hs-CRP and serum levels of CRP in individuals with OSA appeared to be associated with the disease severity. Further, higher AHI appeared to impact on the associations between OSA and CRP/hs-CRP levels. Future studies might consider, if and to what extent interventions on OSA (e.g., using CPAP devices) may favorably impact on CRP/hs-CRP levels and possibly also on weight regulation. While it appeared that the use of CPAP did not change the level of inflammatory markers after 12 weeks among women with Obstructive Sleep Apnea [145] , it would be of clinical and practical importance to know if changes is hs-CRP and CRP would be associated with weight loss among individuals with OSA.

We claim that the present results are of clinical importance: Individuals with OSA appeared to be at increased risk to suffer from higher hs-CRP and CRP levels; such increased inflammatory levels were associated with a higher risk of suffering from further diseases such as early neurological deterioration following stroke [146] or major cardiovascular events in patients with peripheral artery disease [147] . We hold that the present results are also of practical importance, because individuals with higher hs-CRP or CRP levels appeared to be at a dramatically increased risk of reporting a much severe progress of the COVID-19 [148, 149] ; indeed; higher CRP levels were an independent factor to predict the severity of COVID-19 [149] ; given this, we speculate that individuals with OSA and higher hs-CRP and CRP levels might also be at an increased risk to suffer from severe COVID-19. 

Updates on Definition, Consequences, and Management of Obstructive Sleep Apnea

Obstructive Sleep Apnea: Update and Future

Inflammatory milieu and cardiovascular homeostasis in children with obstructive sleep apnea

Myeloid-related protein 8/14 levels in children with obstructive sleep apnoea

Prevalence of obstructive sleep apnea in the general population: A systematic review

Obstructive sleep apnea: Diagnosis, epidemiology, and economics

The epidemiology of adult obstructive sleep apnea

The Relationship of Obesity and Obstructive Sleep Apnea

Predictors of sleep-disordered breathing in commu-nity-dwelling adults: The Sleep Heart Health Study

The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: A systematic review and meta-analysis of observational studies

Serum and Plasma Tumor Necrosis Factor Alpha Levels in Individuals with Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression

Evaluation of serum and plasma inter-leukin-6 levels in obstructive sleep apnea syndrome (OSAS): A meta-analysis and meta-regression. Front

Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6

Obstructive sleep apnea and inflammation: Proof of concept based on two illustrative cyto-kines

The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen

Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects

The genetics of obstructive sleep apnoea

Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction

Serum Inflammatory Markers in Obstructive Sleep Apnea: A Meta-Analysis

Impact of Obstructive Sleep Apnea Syndrome on Endothelial Function, Arterial Stiffening, and Serum Inflammatory Markers: An Updated Meta-analysis and Metaregression of 18 Studies

Is C-reactive protein a marker of obstructive sleep apnea? A meta-analysis

Is C-reactive protein elevated in obstructive sleep apnea? a systematic review and meta-analysis

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis

The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: A meta-analysis

Quantifying heterogeneity in a meta-analysis

Operating characteristics of a rank correlation test for publication bias

Bias in meta-analysis detected by a simple, graphical test

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

Estimating the mean and variance from the median, range, and the size of a sample

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Imbalance in the diurnal salivary testosterone/cortisol ratio in men with severe obstructive sleep apnea: An observational study

Elevated C-Reactive Protein in Patients with Obstructive Sleep Apnea

Increased C-Reactive Protein and Increased Plasma Interleukin-6 May Synergistically Affect the Progression of Coronary Atherosclerosis in Obstructive Sleep Apnea Syndrome

Elevated Levels of C-Reactive Protein and Interleukin-6 in Patients with Obstructive Sleep Apnea Syndrome Are Decreased by Nasal Continuous Positive Airway Pressure

Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea

Protein and Sleep-Disordered Breathing

Increased Carotid Intima-Media Thickness and Serum Inflammatory Markers in Obstructive Sleep Apnea

Serum Cardiovascular Risk Factors in Obstructive Sleep Apnea

Association between lipid peroxidation and inflammation in obstructive sleep apnoea

Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: A sleep clinic cohort study

Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity

Endothelial Dysfunction and C-Reactive Protein in Relation with the Severity of Obstructive Sleep Apnea Syndrome

Decreased Lipoprotein Lipase in Obstructive Sleep Apnea Syndrome

Silent brain infarction and platelet activation in obstructive sleep apnea

Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome

Association of Sleep Apnea Severity and Obesity with Insulin Resistance, C-Reactive Protein, and Leptin Levels in Male Patients with Obstructive Sleep Apnea

Is excessive daytime sleepiness a predictor of carotid atherosclerosis in sleep apnea? Atheroscler

Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi

Plasma Thioredoxin, a Novel Oxidative Stress Marker, in Patients with Obstructive Sleep Apnea Before and after Nasal Continuous Positive Airway Pressure

Obstructive Sleep Apnoea correlates with C-reactive protein in obese Asian Indians

Continuous Positive Airway Pressure Therapy Improves Hypoadiponectinemia in Severe Obese Men with Obstructive Sleep Apnea Without Changes in Insulin Resistance

Endothelium-derived markers and antioxidant status in the blood of obstructive sleep apnea males

Visceral Obesity is Associated with the Metabolic Syndrome and Elevated Plasma Retinol Binding Protein-4 Level in Obstructive Sleep Apnea Syndrome

The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea

Comparison of biomarkers of subclinical lung injury in obstructive sleep apnea

Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea

Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome

Type 2 diabetes and pre-diabetes are associated with obstructive sleep apnea in extremely obese subjects: A cross-sectional study

Cytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apnea

Serum gammaglutamyl transferase activity is an independent predictor for cardiovascular disease in Obstructive Sleep Apnea Syndrome

Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea

Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Independently Associated with Left Ventricular Mass and Myocardial Performance Index in Obstructive Sleep Apnea Syndrome

C-reactive protein and heart rate recovery in middle-aged men with severe obstructive sleep apnea

Elevated levels of serum chemerin in patients with obstructive sleep apnea syndrome

Lack of association between objectively assessed sleep disorders and inflammatory markers among kidney transplant recipients

The relationship between high-sensitivity C-reactive protein levels and the severity of obstructive sleep apnea

Effect of CPAP treatment on endothelial function and plasma CRP levels in patients with sleep apnea

Blood trace minerals concentrations and oxidative stress in patients with obstructive sleep apnea

The evaluation of body composition, adiponectin, C-reactive protein and cho-lesterol levels in patients with obstructive sleep apnea syndrome

Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syn-drome

Elevated serum cystatin C in severe OSA younger men without complications

Gender-Related Changes of the Epicardial Fat Thickness and Leptin in Obstructive Sleep Apnea

Correlation between Inflammatory Markers of Atherosclerosis and Carotid Intima-Media Thickness in Obstructive Sleep Apnea. Molecules

Association of Serum YKL-40 with the Presence and Severity of Obstructive Sleep Apnea Syndrome

Undas, A. Modulation of Inflammatory and Hemostatic Markers in Obstructive Sleep Apnea Patients Treated with Mandibular Advancement Splints: A Parallel, Controlled Trial

Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients

Complete blood count alterations after six months of con-tinuous positive airway pressure treatment in patients with severe obstructive sleep apnea

Impairment of High-Density Lipoprotein Resistance to Lipid Peroxidation and Adipose Tissue Inflammation in Obesity Complicated by Obstructive Sleep Apnea

Arginase activity and nitric oxide levels in patients with obstructive sleep apnea syndrome

Relationship between hepcidin levels and periodic limb movement disorder in patients with obstructive sleep apnea syndrome

Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: A cross-sectional study

Obstructive sleep apnea is independently associated with inflammation and insulin resistance, but not with blood pressure, plasma catecholamines, and endothelial function in obese subjects

Oxidative stress parameters and their correlation with clinical, metabolic and polysomnographic parameters in severe obstructive sleep apnea syndrome

Serum YKL-40/chitinase 3-like protein 1 level is an independent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome

Evaluation of the association of sleep apnea-related systemic inflammation with CRP, ESR, and neutrophil-to-lymphocyte ratio

Serum sLOX-1 Levels Are Correlated with the Presence and Severity of Obstructive Sleep Apnea

Effect of CPAP on New Endothelial Dysfunction Marker, Endocan, in People with Obstructive Sleep Apnea

Cystatin C Levels in Middle-Aged Patients with Obstructive Sleep Apnea Syndrome

Impaired plasma clot lysis and its determinants in patients with obstructive sleep apnea syndrome

Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea

Obstructive sleep apnea combined dyslipidemia render additive effect on increasing atherosclerotic cardiovascular diseases prevalence

Obstructive sleep apnea is associated with elevated high sensitivity C-reactive protein levels independent of obesity: Korean genome and epidemiology study

Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults

Serum midkine levels in patients with obstructive sleep apnoea

Relationship between C-reactive protein levels and obstructive sleep apnea syndrome

Upper airway and systemic inflammation in obstructive sleep apnoea

Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea

Prognostic role of advanced glycation end products in male patients with obstructive sleep apnoea syndrome and hypertension

Evaluation of Inflammatory Markers in a Large Sample of Obstructive Sleep Apnea Patients without Comorbidities

Does Obstructive Sleep Apnea Increase the Risk for Periodontal Disease? A Case-Control Study

Serum levels of magnesium and their relationship with CRP in patients with OSA

Decreased sL-selectin serum levels in sleep apnea syndrome patients with cardiovascular diseases

Modelling obstructive sleep apnea susceptibility using non-invasive inflammatory biomarkers

Evaluation of MIh Scoring System in Diagnosis of Obstructive Sleep Apnea Syndrome

Adropin and Inflammation Biomarker Levels in Male Patients with Obstructive Sleep Apnea: A Link with Glucose Metabolism and Sleep Parameters

Gamma-glutamyl transferase activity as a predictive marker for severity of obstructive sleep apnea syndrome and concomitant hypertension

The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome

Complement system activation in obstructive sleep apnea

Serum heparanase levels are associated with endothelial dysfunction in patients with obstructive sleep apnea

Serum Romo1 is significantly associated with disease severity in patients with obstructive sleep apnea syndrome

Adiponectin, omentin, ghrelin, and visfatin levels in obese patients with severe obstructive sleep apnea

Non-alcoholic fatty liver disease is an independent risk factor for inflammation in obstructive sleep apnea syndrome in obese Asian Indians

The Effects of Obstructive Sleep Apnea on Risk factors for Cardiovascular diseases

Plasm YKL-40 Levels Are Associated with Hypertension in Patients with Obstructive Sleep Apnea

Paraoxonase 1 Gene L55M Polymorphism and Paraoxonase 1 Activity in Obstructive Sleep Apnea Patients

Serum levels of NGAL and cystatin C as markers of early kidney dysfunction in patients with obstructive sleep apnea syndrome

Obstructive sleep apnea causes impairment of the carotid artery in patients with hypertrophic obstructive cardiomyopathy

TNFRSF11B: A potential plasma biomarker for diagnosis of obstructive sleep apnea

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea

Association of serum adiponectin level with cystatin C in male patients with obstructive sleep apnea syndrome

Intramyocellular Lipids, Insulin Resistance, and Functional Performance in Patients with Severe Obstructive Sleep Apnea

Does ischemia-modified albumin level predict severity of obstructive sleep apnea?

Decreased Levels of Anti-Aging Klotho in Obstructive Sleep Apnea

Circulating P-Selectin and Its Glycoprotein Ligand in Nondiabetic Obstructive Sleep Apnea Patients

Relationship between inflammatory factors and arrhythmia and heart rate variability in OSAS patients

Obstructive sleep apnea and liver injury in severely obese patients with nonalcoholic fatty liver disease

Adiposity and low-grade systemic inflammation modulate matrix metalloproteinase-9 levels in Greek children with sleep apnea

Endothelial Progenitor Cells and Vascular Dysfunction in Children with Obstructive Sleep Apnea

Relationship between Sleep Apnea, Fat Distribution, and Insulin Resistance in Obese Children

Macrophage migration inhibitory factor gene polymorphisms and plasma levels in children with obstructive sleep apnea

TREM-1 and Pentraxin-3 Plasma Levels and Their Association with Obstructive Sleep Apnea, Obesity, and Endothelial Function in Children

C-reactive protein and carotid inti-ma-media thickness in children with sleep disordered breathing

A Pro-Inflammatory Role for Nuclear Factor Kappa B in Childhood Obstructive Sleep Apnea Syndrome

Obstructive Sleep Apnea and Obesity are Associated with Reduced GPR 120 Plasma Levels in Children

Lipopolysaccharide-Binding Protein Plasma Levels in Children: Effects of Obstructive Sleep Apnea and Obesity

CD4+T-lymphocyte subsets in nonobese children with obstructive sleep apnea syndrome

Inflammatory cytokines in pediatric obstructive sleep apnea

Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome

Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration

C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity

Obstructive sleep apnea syndrome and cardio-vascular disease: The influence of C-reactive protein

Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo

Effect of continuous positive airway pressure on inflammatory, antioxidant, and depression biomarkers in women with obstructive sleep apnea: A randomized controlled trial

A Systematic Review and Meta-Analysis of Molecular Biomarkers Associated with Early Neurological Deterioration Following Acute Stroke

Systematic Review and Meta-Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in Patients with Peripheral Artery Disease

Association of elevated inflammatory markers and severe COVID-19: A meta-analysis

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Acknowledgments: This work was performed in partial fulfillment of the requirements for a doctorate degree in General Dentistry (Farid Farokhzadeh), in Faculty of Dentistry, Kermanshah University of Medical Sciences, Kermanshah, Iran. Further, we thank the University of Basel (Basel, Switzerland) to care for the Article Processing Charge (APC).

The authors declare no conflict of interest.